38 recruiting. 38 Phase 2, 16 Phase 1, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Recruiting 38 |
| Phase 1 | 16 | Recruiting 16 |
| Phase 3 | 3 | Recruiting 3 |
Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FT839 in Autoimmune Diseases FT839 - ANCA-Associated Vasculitis (AAV), Idiopathic Inflammatory Myositis (IIM) | Phase 1 / Phase 2 | Recruiting | Fate Therapeutics | 446 | 2026-10-01 | 2026-09-02 |
| A Study to Test CRT-402 in Refractory Autoimmune Disease CRT-402 - Autoimmune Diseases, Systemic Lupus Erythematosus | Phase 1 / Phase 2 | Recruiting | Myeloid Therapeutics | 34 | 2026-08-26 | 2026-10-22 |
| Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy CD19 CAR T Arm - Scleroderma, Systemic | Phase 2 | Recruiting | University Hospital, Montpellier | 6 | 2026-06-11 | 2026-10-14 |
| EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc) MTX-474, Placebo - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Recruiting | Mediar Therapeutics | 85 | 2026-04-16 | 2026-10-05 |
| Controlling Hyperactive Immunity With Long-lived Lymphocytes QEL-005 - Diffuse Cutaneous Systemic Sclerosis, Rheumatoid Arthritis (RA) | Phase 1 / Phase 2 | Recruiting | Quell Therapeutics Limited | 16 | 2026-04-10 | 2026-10-19 |
| Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH. umbilical cord blood CD19-BCMA CAR-T cells infusion - Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 45 | 2026-03-18 | 2026-03-03 |
| Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases Depletion of CD3/CD19 in an autologous stem cell transplant - Systemic Lupus Erythematosus, Systemic Sclerosis | Phase 2 | Recruiting | Stephan Grupp MD PhD | 20 | 2026-03-01 | 2025-10-14 |
| A Study of Nemolizumab for the Treatment of Adults With Systemic Sclerosis Nemolizumab, Placebo - Systemic Sclerosis | Phase 2 | Recruiting | Galderma R&D | 162 | 2026-02-20 | 2026-03-31 |
| A Study of AZD0120 in Autoimmune Diseases AZD0120, SOC - Systemic Sclerosis, Idiopathic Inflammatory Myopathies | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 27 | 2026-01-09 | 2026-11-02 |
| A Phase 1/2 Study of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis. PRO-203, Placebo - Healthy Volunteers, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Prolium Bioscience, Inc | 44 | 2025-10-27 | 2026-10-09 |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. Allogeneic NK Cells - Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs) | Phase 2 | Recruiting | Artiva Biotherapeutics, Inc. | 90 | 2025-07-09 | 2026-07-31 |
| Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases anti-CD19 CAR T cell therapy - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc) | Phase 1 / Phase 2 | Recruiting | Peking University Third Hospital | 9 | 2025-07-01 | 2026-09-22 |
| Extracorporeal Photopheresis in Early Diffuse Cutaneous Systemic Sclerosis Extracorporeal Photopheresis (ECP), UVADEX - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Recruiting | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 15 | 2025-05-14 | 2026-10-01 |
| CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH CD19-BCMA CAR-T cells infusion - Refractory Lupus Nephritis, Systemic Sclerosis | Phase 1 / Phase 2 | Recruiting | Beijing GoBroad Hospital | 45 | 2025-04-18 | 2026-07-30 |
| Intralesional Injection of STS in Treatment of Calcinosis Sodium Thiosulfate (STS) - Systemic Sclerosis (SSc), Dermatomyositis | Phase 2 | Recruiting | Robyn T. Domsic, MD, MPH | 20 | 2025-03-17 | 2026-05-05 |
| A Study of Microbiome Transplantation for the Treatment of Constipation and/or Significant Bloating in Patients With Systemic Sclerosis PRIM-DJ2727, Placebo - Constipation, Bloating | Phase 2 | Recruiting | The University of Texas Health Science Center, Houston | 21 | 2025-03-03 | 2026-07-08 |
| Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis TOP-N53, Sildenafil, TOP-N53 vehicle - Digital Ulcers in Systemic Sclerosis | Phase 2 | Recruiting | Topadur Pharma AG | 15 | 2025-02-04 | 2026-10-01 |
| Efficacy and Safety of Telitacicept in the Treatment of Systemic Sclerosis Telitacicept, Mycophenolate Mofetil - Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 38 | 2025-01-06 | 2025-02-11 |
| BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases BCMA-CD19 CAR-T therapy - Systemic Lupus Erythematosus, Inflammatory Myopathy | Phase 2 | Recruiting | Peking University People's Hospital | 50 | 2024-12-26 | 2025-04-02 |
| Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases CAR T cell - Lupus Erythematosus, Systemic, System; Sclerosis | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 8 | 2024-11-29 | 2025-04-11 |
Showing 20 of 38. Sign in to see all of them.
Scleroderma, Diffuse (16) · Lupus Erythematosus, Systemic (8) · Myositis (8) · Lung Diseases, Interstitial (7) · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (6) · Arthritis, Rheumatoid (5) · Dermatomyositis (5) · Autoimmune Diseases (4) · Lupus Nephritis (4) · Sjogren's Syndrome (4) · Polymyositis (3) · Antiphospholipid Syndrome (2) · digital ulcers (2) · Behcet Syndrome (1)
Skin and Connective Tissue Diseases (38) · Connective Tissue Diseases (37) · Skin Diseases (37) · Immune System Diseases (16) · Musculoskeletal Diseases (13) · Autoimmune Diseases (12) · Muscular Diseases (12) · Nervous System Diseases (12) · Neuromuscular Diseases (12) · Lung Diseases (9) · Respiratory Tract Diseases (9) · Arthritis (8) · Cardiovascular Diseases (8) · Joint Diseases (8) · Rheumatic Diseases (8)
Cyclophosphamide (3) · Mycophenolic Acid (2) · Sildenafil Citrate (2) · Alemtuzumab (1) · Antilymphocyte Serum (1) · BI 1015550 (1) · Filgrastim (1) · Granulocyte-Macrophage Colony-Stimulating Factor (1) · Immunoglobulins, Intravenous (1) · Immunotherapy, Adoptive (1) · Mesna (1) · Methoxsalen (1) · Photopheresis (1) · Rituximab (1) · Thiotepa (1)
Beijing GoBroad Hospital (2) · Artiva Biotherapeutics, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · AstraZeneca (1) · Cabaletta Bio (1) · Centre hospitalier de l'Université de Montréal (CHUM) (1) · Essen Biotech (1) · Fate Therapeutics (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Galderma R&D (1) · GlaxoSmithKline (1) · Jiangsu Renocell Biotech Company (1) · Johns Hopkins University (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · M.D. Anderson Cancer Center (1)
United States (16) · China (9) · France (9) · Australia (5) · Germany (5) · Spain (5) · Italy (4) · United Kingdom (4) · Canada (3) · Brazil (2) · Mexico (2) · Netherlands (2) · Poland (2) · Romania (2) · South Korea (2)
Adam Raff, MD, PhD (1) · Benjamin Chaigne, MD (1) · Caitlin Elgarten, MD (1) · Chitra Hosing, MD (1) · Christian Jorgensen, PUPH (1) · Dr. Janet E Pope, MD PhD (1) · Georg Schett, Prof. Dr. med. univ. (1) · Jing Wang (1) · Kevin O'Shea (1) · Lisa Carey (1) · Luc Mouthon, MD-PhD (1) · Maria Antonietta D'Agostino (1)
PMID 15942915, PMID 22227955, PMID 30127049, PMID 38689245, PMID 39544897, PMID 41217519, PMID 41501497, PMID 42177178, PMID 42309868
2025 (2), 2015 (1), 2019 (1), 2023 (1), P50AR080612 (1)